Related Experiment Video
Updated: Mar 26, 2026

Isolation of Papillary and Reticular Fibroblasts from Human Skin by Fluorescence-activated Cell Sorting
Published on: May 7, 2019
Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21
Diana Ronai Dunshee1, Travis W Bainbridge2, Noelyn M Kljavin3
1From Molecular Biology.
Abstract:
FGF21 is a stress-induced hormone with potent anti-obesity, insulin-sensitizing, and hepatoprotective properties. Although proteolytic cleavage of recombinant human FGF21 in preclinical species has been observed previously, the regulation of endogenously produced FGF21 is not well understood. Here we identify fibroblast activation protein (FAP) as the enzyme that cleaves and inactivates human FGF21. A selective chemical inhibitor, immunodepletion, or genetic deletion of Fap stabilized recombinant human FGF21 in serum. In addition, administration of a selective FAP inhibitor acutely increased circulating intact FGF21 levels in cynomolgus monkeys. On the basis of our findings, we propose selective FAP inhibition as a potential therapeutic approach to increase endogenous FGF21 activity for the treatment of obesity, type 2 diabetes, non-alcoholic steatohepatitis, and related metabolic disorders.
Insights
Fibroblast activation protein (FAP) inactivates the hormone FGF21. Inhibiting FAP stabilizes FGF21, offering a potential therapy for metabolic disorders like obesity and type 2 diabetes.
Area of Science:
- Endocrinology
- Metabolic disease research
- Enzymology
Background:
- Fibroblast activation protein (FAP) is an enzyme implicated in various physiological and pathological processes.
- Fibroblast Growth Factor 21 (FGF21) is a hormone known for its metabolic benefits, including anti-obesity and insulin-sensitizing effects.
- The endogenous regulation and degradation pathways of FGF21 are not fully elucidated.
Purpose of the Study:
- To identify the specific enzyme responsible for the proteolytic cleavage and inactivation of endogenously produced human FGF21.
- To investigate the potential of targeting this enzyme for therapeutic intervention in metabolic diseases.
Main Methods:
- Utilized biochemical assays to identify the protease cleaving human FGF21.
- Employed a selective chemical inhibitor of FAP, FAP immunodepletion, and genetic deletion of Fap to assess its effect on FGF21 stability.
- Administered a selective FAP inhibitor to cynomolgus monkeys to measure changes in circulating intact FGF21 levels.
Main Results:
- Identified fibroblast activation protein (FAP) as the primary enzyme that cleaves and inactivates human FGF21.
- Demonstrated that FAP inhibition (chemical, immunologic, or genetic) stabilizes recombinant human FGF21 in serum.
- Showed that acute administration of a selective FAP inhibitor increases circulating intact FGF21 levels in non-human primates.
Conclusions:
- Fibroblast activation protein (FAP) plays a key role in the degradation of FGF21.
- Selective FAP inhibition represents a promising therapeutic strategy to enhance endogenous FGF21 activity.
- This approach holds potential for treating metabolic disorders such as obesity, type 2 diabetes, and non-alcoholic steatohepatitis.
Related Concept Videos
Introduction to Fibroblasts
TGF - β Signaling Pathway
Actin Filament Depolymerization
In F-actin, the ADF/cofilin proteins...
Amplifying Signals via Enzymatic Cascade
Clot Retraction and Fibrinolysis
Intracellular Signaling Affects Focal Adhesions
Some...

